Insulin Degludec (Tresiba)

1. Overview

Insulin degludec is an ultra-long-acting basal insulin analog developed by Novo Nordisk and produced by recombinant DNA technology in Saccharomyces cerevisiae. It represents the most advanced protraction strategy among basal insulins, employing a fundamentally novel mechanism -- soluble multi-hexamer chain formation at the injection site -- to achieve the longest half-life (approximately 25 hours) and duration of action (exceeding 42 hours) of any commercially available insulin [1][2][3]. Insulin degludec was first approved by the EMA in January 2013 and subsequently by the FDA on September 25, 2015, as Tresiba, available in both U-100 (100 units/mL) and U-200 (200 units/mL) concentrations.

The molecule is a 51-amino acid, two-chain peptide (A-chain: 21 amino acids; B-chain: 29 amino acids) with the molecular formula C274H411N65O81S6 and a molecular weight of approximately 6103.97 Da [1][2][19]. It differs from native human insulin by two modifications: (1) deletion of threonine at position B30 (des-B30), which is also absent in porcine insulin and does not significantly affect insulin receptor binding; and (2) attachment of a 16-carbon hexadecanedioic acid (palmitic fatty diacid) side chain to the epsilon-amino group of lysine at position B29 via a gamma-glutamic acid linker. This acylation strategy -- designated B29Lys(N-epsilon-hexadecanedioyl-gamma-Glu) -- is central to the unique multi-hexamer depot mechanism that defines degludec's pharmacology [1][20].

Insulin degludec is also available as a fixed-ratio combination with liraglutide (IDegLira, marketed as Xultophy), approved by the FDA on November 21, 2016. Each dose-step delivers 1 unit of insulin degludec plus 0.036 mg of liraglutide, combining the complementary mechanisms of basal insulin and GLP-1 receptor agonism [12][13].

Molecular Weight

~6103.97 Da

Molecular Formula

C274H411N65O81S6

Structure

51 amino acids (A-chain 21 aa, B-chain 29 aa, des-B30); two-chain disulfide-linked

Key Modification

B29Lys(N-epsilon-hexadecanedioyl-gamma-Glu) des(B30); C16 fatty diacid acylation

Half-life

~25 hours (longest of any basal insulin)

Duration of Action

Greater than 42 hours (up to 48+ hours at steady state)

Time to Steady State

3-4 days

Bioavailability

~80% (subcutaneous)

Day-to-Day Variability

4-fold lower coefficient of variation than insulin glargine U-100

Routes

Subcutaneous injection (approved)

FDA Status (Tresiba)

Approved September 25, 2015 (type 1 and type 2 diabetes, U-100 and U-200)

FDA Status (Xultophy)

Approved November 21, 2016 (IDegLira, fixed-ratio combination with liraglutide)

2. Mechanism of Action

Multi-Hexamer Chain Formation -- A Novel Protraction Mechanism

The ultra-long duration of insulin degludec is achieved through a unique self-association mechanism fundamentally different from those of insulin glargine (microprecipitate formation) and insulin detemir (albumin binding) [1][14][20].

In the pharmaceutical formulation (pH 7.4, containing phenol and zinc), insulin degludec exists as stable di-hexamers, with the hexadecanedioic acid fatty diacid chains bridging between adjacent hexamers through hydrophobic interactions. Upon subcutaneous injection, phenol rapidly diffuses away from the depot. In the absence of phenol, the zinc-stabilized hexamers undergo a conformational reorganization, and the fatty diacid side chains mediate extensive inter-hexamer contacts, driving the formation of long, soluble multi-hexamer chains [1][20]. These are not precipitates (unlike insulin glargine) but rather soluble supramolecular assemblies that can extend to hundreds of hexamers in length.

The critical insight is the open-ended, linear nature of these chains [1][20]. Insulin degludec monomers can only dissociate from the terminal hexamers at the ends of the chains, resulting in an extremely slow and steady rate of monomer release into the systemic circulation. This terminal dissociation mechanism provides:

• An ultra-long half-life of approximately 25 hours (versus approximately 12 hours for glargine U-100)
• A duration of glucose-lowering action exceeding 42 hours at steady state
• An extraordinarily flat pharmacodynamic profile with no discernible peak
• Day-to-day pharmacodynamic variability 4-fold lower than insulin glargine U-100 (coefficient of variation approximately 20% versus approximately 82%) [3][15]

Albumin Binding as a Secondary Buffer

After dissociation from the multi-hexamer chains and absorption into the circulation, insulin degludec monomers also bind reversibly to serum albumin via the fatty diacid side chain (similar to insulin detemir, though with higher affinity due to the longer C16 chain) [2][14]. This albumin binding provides an additional buffering mechanism, further smoothing the pharmacokinetic profile and reducing variability. Only the free (unbound) fraction is available to bind insulin receptors on target tissues.

Insulin Receptor Signaling

Once dissociated from albumin, insulin degludec binds to the insulin receptor with affinity and activity comparable to native human insulin. The des-B30 deletion and the B29 acylation do not significantly alter insulin receptor binding or downstream signaling through the PI3K/Akt and Ras/MAPK pathways [2]. Metabolic effects are fully preserved, including stimulation of glucose uptake, glycogen synthesis, suppression of hepatic glucose output, and inhibition of lipolysis.

U-100 vs U-200 Bioequivalence

Unlike insulin glargine (where U-100 and U-300 have different pharmacokinetic profiles due to the surface-area-dependent microprecipitate mechanism), insulin degludec U-100 and U-200 are bioequivalent [2][19]. The multi-hexamer chain mechanism is independent of injection volume and depot surface area. The U-200 concentration simply allows delivery of higher doses in half the volume, improving convenience for patients requiring large doses without altering the pharmacokinetic or pharmacodynamic profile.

3. Researched Applications

Basal Insulin Therapy in Type 1 Diabetes (Strong Evidence -- FDA Approved)

The BEGIN Basal-Bolus Type 1 trial (Heller et al., 2012) randomized 629 adults with type 1 diabetes to insulin degludec or insulin glargine U-100, both in combination with mealtime insulin aspart [4]. Over 52 weeks, degludec was noninferior for HbA1c reduction, with 25% lower rates of nocturnal confirmed hypoglycemia (rate ratio 0.75; p=0.024) at equivalent glycemic control. Fasting plasma glucose was significantly lower with degludec, reflecting the more stable basal insulin coverage.

The SWITCH 1 trial (Lane et al., 2017) was a rigorous double-blind crossover study in 501 adults with type 1 diabetes at increased hypoglycemia risk [10]. This design eliminated between-patient variability as a confounder. Insulin degludec reduced the rate of overall symptomatic hypoglycemia by 11% (rate ratio 0.89; p=0.035) and nocturnal symptomatic hypoglycemia by 36% (rate ratio 0.64; p less than 0.001) compared with glargine U-100, at equivalent HbA1c.

Basal Insulin Therapy in Type 2 Diabetes (Strong Evidence -- FDA Approved)

The BEGIN Once Long trial (Zinman et al., 2012) demonstrated noninferiority of degludec to glargine U-100 in 1,030 insulin-naive adults with T2D, with 36% lower nocturnal confirmed hypoglycemia (rate ratio 0.64; p=0.023) [6]. The BEGIN Basal-Bolus Type 2 trial (Garber et al., 2012, n=1,006) showed noninferiority for HbA1c with 18% fewer overall confirmed hypoglycemic episodes and 25% fewer nocturnal episodes [5].

The SWITCH 2 trial (Wysham et al., 2017) confirmed these advantages in a double-blind crossover design in 721 T2D patients at hypoglycemia risk, demonstrating 30% lower overall symptomatic hypoglycemia (rate ratio 0.70; p less than 0.001) and 51% lower severe hypoglycemia (rate ratio 0.49; p=0.023) with degludec versus glargine U-100 [11].

A pre-planned meta-analysis of all Phase 3 BEGIN trials confirmed consistent hypoglycemia reductions with degludec versus glargine across both type 1 and type 2 diabetes populations [18].

Flexible Dosing -- The BEGIN Flex Study

The ultra-long duration of action of insulin degludec enables clinically meaningful dosing flexibility. The BEGIN Flex trial (Meneghini et al., 2013) demonstrated that degludec administered at variable daily times (creating dosing intervals ranging from 8 to 40 hours between injections) achieved noninferior glycemic control compared with both fixed-time degludec and glargine U-100 [7]. This flexibility is unique among basal insulins and is particularly valuable for patients with variable schedules, shift workers, or those prone to missed doses.

DEVOTE Cardiovascular Outcomes Trial (Strong Evidence)

The DEVOTE trial was a landmark Phase 3, double-blind, event-driven cardiovascular outcomes trial (CVOT) that randomized 7,637 adults with type 2 diabetes at high cardiovascular risk to insulin degludec or insulin glargine U-100, titrated to equivalent fasting glucose targets [8].

After a median follow-up of 1.99 years (732 events), insulin degludec was noninferior to insulin glargine U-100 for the primary composite endpoint of 3-point MACE (cardiovascular death, nonfatal MI, or nonfatal stroke): HR 0.91 (95% CI 0.78-1.06; p for noninferiority less than 0.001). While not powered for superiority, the point estimate numerically favored degludec.

The key secondary finding was a 40% reduction in severe hypoglycemia with degludec versus glargine (rate ratio 0.60; 95% CI 0.48-0.76; p less than 0.001) and a 53% reduction in nocturnal severe hypoglycemia (rate ratio 0.47; 95% CI 0.31-0.73) [8]. This was particularly notable because the trial used treat-to-target design with equivalent glycemic targets, meaning the hypoglycemia reduction was achieved without compromising glycemic control.

The DEVOTE 3 post-hoc analysis demonstrated that severe hypoglycemia was significantly associated with subsequent increased risk of MACE (HR 2.05; 95% CI 1.26-3.33) and all-cause death (HR 2.51; 95% CI 1.60-3.96) [9]. This finding provides important clinical context for the hypoglycemia advantage of degludec, suggesting that reducing severe hypoglycemia may translate to reduced cardiovascular risk.

Head-to-Head Comparisons with Insulin Glargine U-300 (Toujeo)

Two prospective head-to-head trials compared the two second-generation basal insulins:

The BRIGHT trial (n=929) in insulin-naive T2D showed no clinically meaningful differences between degludec U-100 and glargine U-300 for HbA1c reduction (both reaching approximately 7.0% from 8.6%), though glargine U-300 showed numerically lower hypoglycemia during the first 12 weeks of titration [16].

The CONCLUDE trial (n=1,609) in insulin-treated T2D at hypoglycemia risk found no significant difference for the primary endpoint (overall symptomatic hypoglycemia). Secondary endpoints favored degludec for nocturnal symptomatic hypoglycemia (rate ratio 0.63) and severe hypoglycemia (rate ratio 0.20), though degludec was associated with greater weight gain [17].

IDegLira (Xultophy) -- Fixed-Ratio Combination with Liraglutide

The DUAL clinical trial program established the efficacy of the insulin degludec/liraglutide fixed-ratio combination. DUAL I (n=1,663) showed that IDegLira reduced HbA1c by -1.9% versus -1.4% (degludec alone) versus -1.3% (liraglutide alone), with less hypoglycemia and weight neutrality compared with degludec alone [12]. DUAL II (n=413) confirmed that the liraglutide component provided substantial additional glycemic benefit beyond insulin intensification, with HbA1c reduction of -1.9% versus -0.9% with degludec alone at equivalent insulin dose [13].

4. Clinical Evidence Summary

5. Dosing in Research

Type 2 Diabetes -- Initiation (Tresiba). Current guidelines recommend initiating insulin degludec at 10 units once daily, administered subcutaneously at any consistent time of day. The injection can be given in the abdomen, thigh, or upper arm, with rotation of sites. Titration is by 2 units every 3-4 days to achieve a fasting plasma glucose target of 80-130 mg/dL (4.4-7.2 mmol/L). The ultra-long half-life means that 3-4 days are required to reach steady state, and premature dose adjustments should be avoided [19].

Type 1 Diabetes. Insulin degludec provides the basal component (approximately 40-50% of total daily insulin dose), with the remainder as prandial rapid-acting insulin. Starting dose is approximately 0.2 units/kg/day or one-third of total daily insulin. Same titration principles apply [19].

Flexible Dosing. The BEGIN Flex study validated flexible injection timing with degludec, demonstrating that intervals of 8-40 hours between doses did not compromise glycemic control [7]. The prescribing information recommends that if a dose is missed, it may be injected at any time, and the patient should return to the usual schedule the following day, with a minimum of 8 hours between any two doses.

Switching from Other Basal Insulins. When switching from once-daily insulin glargine or detemir, the initial degludec dose should be the same number of units. When switching from twice-daily basal insulin, the degludec dose should be reduced by approximately 20% and then titrated to target [19].

DEVOTE Trial Dosing. Both degludec and glargine arms were titrated to a fasting self-measured plasma glucose target of 71-90 mg/dL (3.9-5.0 mmol/L), with a median achieved dose of approximately 0.5-0.6 units/kg/day [8].

IDegLira (Xultophy). Starting dose is 16 dose-steps once daily (equivalent to 16 units degludec + 0.58 mg liraglutide), titrated by 2 dose-steps every 3-4 days to a maximum of 50 dose-steps/day (50 units degludec + 1.8 mg liraglutide) [12].

6. Safety and Side Effects

The safety profile of insulin degludec is well-characterized across the BEGIN program, SWITCH trials, DEVOTE CVOT, and extensive postmarketing experience.

Hypoglycemia is the most significant adverse effect of any insulin therapy. Insulin degludec's key safety advantage is its consistently lower hypoglycemia risk compared with insulin glargine U-100, particularly for severe and nocturnal hypoglycemia. In DEVOTE, severe hypoglycemia was 40% lower with degludec (rate ratio 0.60; p less than 0.001) and nocturnal severe hypoglycemia was 53% lower [8]. The DEVOTE 3 analysis linking severe hypoglycemia to subsequent cardiovascular events and mortality underscores the clinical significance of this advantage [9]. The ultra-flat pharmacodynamic profile and low day-to-day variability are the mechanistic basis for reduced hypoglycemia risk.

Weight gain occurs as with all insulin therapy. In DEVOTE, weight gain was similar between degludec and glargine. In the CONCLUDE trial comparing degludec with glargine U-300, greater weight gain was observed with degludec. When combined with liraglutide (IDegLira/Xultophy), the weight-sparing effect of the GLP-1 RA component provides weight neutrality [12].

Cardiovascular safety. DEVOTE definitively demonstrated cardiovascular safety, with no excess risk of MACE, heart failure, or cardiovascular death. The point estimate numerically favored degludec (HR 0.91 for MACE), though superiority was not demonstrated [8].

Injection-site reactions are uncommon and comparable to other basal insulins. Lipodystrophy may occur with repeated injections at the same site.

Immunogenicity. Anti-insulin antibody formation is low and comparable to insulin glargine. Cross-reactive antibodies to native human insulin have not been a clinical concern.

Cancer risk. No signal for increased cancer risk has been observed in clinical trials, including DEVOTE. The des-B30 modification and fatty acid acylation do not enhance IGF-1 receptor binding or mitogenic signaling.

Allergic reactions. Rare systemic allergic reactions have been reported, consistent with the insulin analog class.

Contraindications. Insulin degludec is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin degludec or any excipient. It should not be administered intravenously or used in insulin infusion pumps.

Drug interactions. Same interaction profile as other basal insulins: increased hypoglycemia risk with sulfonylureas, ACE inhibitors, MAO inhibitors, and other insulin sensitizers or secretagogues.

7. Pharmacokinetics

Insulin degludec employs a unique multi-hexamer chain depot mechanism that is fundamentally distinct from the microprecipitate depot of insulin glargine or the albumin-binding protraction of insulin detemir [1][14][20].

Depot formation. In the pharmaceutical formulation (pH 7.4, with phenol and zinc), degludec exists as stable di-hexamers. Upon subcutaneous injection, phenol diffuses away, and the zinc-stabilized hexamers reorganize into long, soluble multi-hexamer chains via fatty diacid-mediated inter-hexamer contacts. Monomers dissociate only from the terminal ends of these chains, producing an extremely slow and steady absorption rate [1][20].

Absorption. Time to reach steady-state plasma concentration is 3-4 days with once-daily dosing. At steady state, the concentration-time profile is essentially flat with no discernible peak. The within-subject day-to-day variability (coefficient of variation) of glucose-lowering effect is approximately 20% for degludec versus approximately 82% for glargine U-100 -- a 4-fold reduction in pharmacodynamic variability [3][15].

Distribution. After absorption, degludec monomers bind reversibly to serum albumin via the C16 fatty diacid side chain (greater than 99% protein-bound). This albumin binding serves as a secondary pharmacokinetic buffer, further smoothing the profile. Volume of distribution is approximately 0.1 L/kg. Only the free (unbound) fraction binds insulin receptors [2][14].

Metabolism. Degraded by insulin-degrading enzyme (IDE) and related proteases, primarily in the liver and kidney, following the same pathways as endogenous insulin. The fatty diacid side chain undergoes beta-oxidation. No active metabolites [19].

Elimination. Terminal half-life is approximately 25 hours (the longest of any commercial basal insulin), compared with approximately 12 hours for glargine U-100 and approximately 5-7 hours for detemir. Duration of glucose-lowering action exceeds 42 hours at steady state. Clearance is approximately 1.3 L/h. The ultra-long half-life enables true once-daily dosing with flexible timing (8-40 hour intervals validated in BEGIN Flex) [7].

U-100 vs U-200 bioequivalence. Unlike glargine (where U-100 and U-300 have different PK profiles due to the microprecipitate mechanism's surface-area dependence), degludec U-100 and U-200 are bioequivalent because the multi-hexamer chain mechanism is independent of injection volume and depot geometry [2][19].

8. Dose-Response Relationship

Fasting glucose titration. Insulin degludec demonstrates a predictable dose-response relationship for fasting plasma glucose, with titration algorithms validated across the BEGIN program. The recommended approach is a 2-unit increase every 3-4 days targeting FPG 80-130 mg/dL (4.4-7.2 mmol/L). The 3-4 day interval is critical because the 25-hour half-life means that dose changes require 3-4 days to reach new steady-state [19].

Hypoglycemia dose-response. The DEVOTE trial revealed a non-linear relationship between insulin dose and hypoglycemia risk that distinctly favors degludec. At equivalent achieved fasting glucose targets, degludec produced 40% lower severe hypoglycemia (RR 0.60, p less than 0.001) than glargine U-100, with the benefit amplified for nocturnal severe hypoglycemia (53% lower, RR 0.47) [8]. This indicates that degludec achieves a superior glucose-lowering-to-hypoglycemia ratio at all dose levels.

Dose range. In clinical practice, degludec doses range from approximately 10 units/day (insulin-naive T2D initiation) to greater than 100 units/day in highly insulin-resistant patients. The U-200 formulation allows delivery of up to 160 units in a single injection. In the DEVOTE trial, the median achieved dose was approximately 0.5-0.6 units/kg/day [8].

IDegLira dose-response. In the fixed-ratio combination with liraglutide (Xultophy), the dose-response relationship reflects complementary mechanisms: each dose-step increase adds 1 unit of degludec (reducing fasting glucose) and 0.036 mg of liraglutide (providing GLP-1 RA effects). DUAL I showed that this combination achieved -1.9% HbA1c reduction versus -1.4% for degludec alone at comparable insulin doses, demonstrating a supra-additive effect [12].

9. Comparative Effectiveness

Degludec vs glargine U-100 (Lantus). The most extensively studied comparison. Across all BEGIN trials and the SWITCH crossover studies, degludec is consistently noninferior for HbA1c reduction with significantly lower hypoglycemia rates: 25% lower nocturnal hypoglycemia in T1D (BEGIN Basal-Bolus), 36% lower nocturnal hypoglycemia in insulin-naive T2D (BEGIN Once Long), and 40% lower severe hypoglycemia in DEVOTE [4][6][8]. The SWITCH trials (double-blind crossover design) confirmed these advantages in hypoglycemia-prone populations: 36% lower nocturnal hypoglycemia in T1D (SWITCH 1) and 30% lower overall symptomatic hypoglycemia in T2D (SWITCH 2) [10][11].

Degludec vs glargine U-300 (Toujeo). The BRIGHT trial (insulin-naive T2D, n=929) found no meaningful differences in HbA1c reduction or overall hypoglycemia, though glargine U-300 had numerically lower hypoglycemia during the initial titration period (first 12 weeks) [16]. The CONCLUDE trial (insulin-treated T2D, n=1,609) found no difference in the primary endpoint (overall symptomatic hypoglycemia) but favored degludec for nocturnal hypoglycemia (RR 0.63) and severe hypoglycemia (RR 0.20), with greater weight gain observed with degludec [17]. Overall, the two second-generation basal insulins have similar efficacy and safety profiles.

Degludec vs detemir (Levemir). Degludec has a substantially longer half-life (25 h vs 5-7 h) and flatter profile than detemir, which often requires twice-daily dosing. Head-to-head trials in the BEGIN program used detemir as the comparator for the T1D basal-bolus regimen, and degludec achieved lower fasting glucose and less nocturnal hypoglycemia.

Dosing flexibility advantage. Degludec is the only basal insulin with validated flexible dosing (8-40 hour intervals between injections), making it uniquely suited for patients with irregular schedules, shift workers, or those who frequently miss doses [7].

10. Enhanced Safety Profile

Cardiovascular safety. The DEVOTE trial (n=7,637, median 1.99 years) definitively established cardiovascular safety: HR 0.91 (95% CI 0.78-1.06) for 3-point MACE, with no excess heart failure, cardiovascular death, or all-cause mortality [8]. The DEVOTE 3 analysis demonstrated that severe hypoglycemia was associated with a 2-fold increased risk of subsequent MACE (HR 2.05) and a 2.5-fold increased risk of all-cause death (HR 2.51), providing clinical context for the importance of degludec's lower severe hypoglycemia rates [9].

Severe hypoglycemia reduction. The 40% reduction in severe hypoglycemia versus glargine U-100 in DEVOTE (achieved at equivalent glycemic targets) is clinically transformative for high-risk patients, particularly the elderly, those with cardiovascular disease, and patients with hypoglycemia unawareness [8].

Renal impairment. Insulin degludec can be used in all stages of renal impairment, including dialysis. However, as with all insulins, reduced renal clearance in advanced CKD often necessitates dose reduction (typically 10-25% in eGFR less than 30 mL/min). Intensified glucose monitoring is recommended [19].

Hepatic impairment. Hepatic metabolism of insulin is reduced in liver disease. Dose reduction and careful monitoring are recommended. No specific contraindication exists.

Pregnancy. Limited pregnancy data. Insulin degludec is not specifically indicated for pregnancy, and insulin aspart and lispro (for prandial coverage) combined with NPH or detemir (with more extensive pregnancy data) remain preferred. However, observational data suggest no adverse signals, and degludec may be continued in women who become pregnant while on therapy.

Cancer risk. No signal for increased cancer risk in DEVOTE or the BEGIN program. The des-B30 modification and fatty acid acylation do not enhance IGF-1 receptor binding or mitogenic signaling [19].

Drug interactions. Standard basal insulin interaction profile. Increased hypoglycemia risk when combined with sulfonylureas, GLP-1 RAs, ACE inhibitors, or other insulin sensitizers. Sulfonylurea dose reduction is typically needed when adding or intensifying basal insulin.

Contraindications. Hypoglycemia episodes, hypersensitivity to degludec or excipients. Must not be administered intravenously or used in insulin pumps (the multi-hexamer chain mechanism is designed for subcutaneous depot, and IV or pump use would bypass the protraction mechanism) [19].

11. Related Peptides

See also: Insulin Glargine (Lantus / Toujeo), Insulin Aspart (NovoRapid / NovoLog), Insulin Lispro (Humalog), Liraglutide (Victoza / Saxenda), Semaglutide (Ozempic / Wegovy)

12. References

1. [1] Jonassen I, Havelund S, Hoeg-Jensen T, et al. (2012). Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. DOI PubMed
2. [2] Haahr H, Heise T. (2014). A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. DOI PubMed
3. [3] Heise T, Nosek L, Bottcher SG, et al. (2012). Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. DOI PubMed
4. [4] Heller S, Buse J, Fisher M, et al. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1). Lancet. DOI PubMed
5. [5] Garber AJ, King AB, Del Prato S, et al. (2012). Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2). Lancet. DOI PubMed
6. [6] Zinman B, Philis-Tsimikas A, Cariou B, et al. (2012). Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes (BEGIN Once Long). Diabetes Care. DOI PubMed
7. [7] Meneghini L, Atkin SL, Gough SCL, et al. (2013). The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily (BEGIN Flex). Diabetes Care. DOI PubMed
8. [8] Marso SP, McGuire DK, Zinman B, et al. (2017). Efficacy and safety of degludec versus glargine in type 2 diabetes (DEVOTE). N Engl J Med. DOI PubMed
9. [9] Pieber TR, Marso SP, McGuire DK, et al. (2018). DEVOTE 3 -- temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. DOI PubMed
10. [10] Lane W, Bailey TS, Gerber RA, et al. (2017). Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes -- the SWITCH 1 randomized clinical trial. JAMA. DOI PubMed
11. [11] Wysham C, Bhargava A, Chaykin L, et al. (2017). Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes -- the SWITCH 2 randomized clinical trial. JAMA. DOI PubMed
12. [12] Gough SCL, Bode B, Woo V, et al. (2014). Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone -- results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes (DUAL I). Lancet Diabetes Endocrinol. DOI PubMed
13. [13] Buse JB, Vilsboll T, Thurman J, et al. (2015). Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) (DUAL II). Diabetes Care. DOI PubMed
14. [14] Heinemann L, Home PD, Hompesch M. (2019). Differentiating basal insulin preparations -- understanding how they work explains why they are different. Adv Ther. DOI PubMed
15. [15] Heise T, Hermanski L, Nosek L, et al. (2012). Insulin degludec -- four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. DOI PubMed
16. [16] Rosenstock J, Cheng A, Engel SS, et al. (2018). More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes -- the randomized head-to-head BRIGHT trial. Diabetes Care. DOI PubMed
17. [17] Philis-Tsimikas A, Klonoff DC, Engel SS, et al. (2020). Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes -- the randomised, head-to-head CONCLUDE trial. Diabetologia. DOI PubMed
18. [18] Ratner RE, Gough SCL, Mathieu C, et al. (2013). Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes -- a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. DOI PubMed
19. [19] Novo Nordisk. (2023). Tresiba (insulin degludec injection) -- FDA prescribing information. FDA Label. PubMed
20. [20] Kurtzhals P, Heise T, Strauss HM, et al. (2011). Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. DOI PubMed